Morgan Stanley downgraded ShockWave Medical (SWAV) to Equal Weight from Overweight with a price target of $335, up from $285, following the recently announced agreement for an acquisition of the company by Johnson & Johnson (JNJ). The deal is expected to close by mid-year 2024 and the firm moves its price target to be in-line with the acquisition price.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on SWAV:
- ShockWave Medical downgraded to Market Perform from Outperform at Leerink
- ShockWave Medical downgraded to Hold from Buy at Canaccord
- ShockWave Medical downgraded to Neutral from Overweight at Piper Sandler
- Krispy Kreme upgraded, Altice USA downgraded: Wall Street’s top analyst calls
- M&A News: Johnson & Johnson (NYSE:JNJ) Enters Into $13.1B Shockwave Medical Deal
